Coya Therapeutics FY2025 net loss $21.2M; cash $46.8M, ALS trial enrolling

Coya Therapeutics, Inc.

Cash and cash equivalents $46.8M at Dec 31, 2025; collaboration revenue $7.9M (up from $3.6M).
R&D expenses $16.7M (up $4.8M); net loss $21.2M vs $14.9M in FY2024.
COYA 302 ALSTARS Phase 2 trial actively enrolling across ~25 sites in US and Canada.
FDA accepted IND for COYA 302 in frontotemporal dementia (FTD); Phase 2a expected 2H2026.
Completed $23M public offering and $11.1M private placement; cash runway into 2H2027.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Coya Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $21.2 million.

Period: the year ended December 31, 2025
Net income: $21.2 million
Result: reported results

Exact text from the filing

Net loss was $21.2 million for the year ended December 31, 2025, compared to net loss of $14.9 million for the year ended December 31, 2024.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

Coya Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-107276

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.